The Spanish Biotech Sector - presentation at BioAsia 2013
Upcoming SlideShare
Loading in...5
×
 

The Spanish Biotech Sector - presentation at BioAsia 2013

on

  • 521 views

The Spanish Biotech Sector - presentation at BioAsia 2013 ...

The Spanish Biotech Sector - presentation at BioAsia 2013
By - Juan Carlos Cortés
International Director, Centre for the Development of Industrial Technology, Ministry of Economy & Competitiveness, Spain

Statistics

Views

Total Views
521
Views on SlideShare
521
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

The Spanish Biotech Sector - presentation at BioAsia 2013 The Spanish Biotech Sector - presentation at BioAsia 2013 Presentation Transcript

  • The Spanish Biotech sector in figures Juan Carlos Cortés International Director Centre for the Development of Industrial Technology Ministry of Economy & CompetitivenessUNIÓN EUROPEAFondo Europeo deDesarrollo Regional (FEDER) 1 (07/02/2013)Una manera de hacer Europa
  • The Spanish Biotech sector• A young sector, 15 years old.• Internationalization is part of its DNA.• Success depends on the capacity to export.• Crucial: joint projects and technology exchange agreements. Spain: • Biotech industry growth in the last four years 350% • A key player in R&D, spin-offs, research and collaboration. • Biotech: a key sector in the knowledge economy UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 2 (07/02/2013) Una manera de hacer Europa
  • The Spanish Biotech sector now Source: Genoma España/ASEBIO• Nº enterprises: 1.715 (617 EB+1.098 EIB)• Nº personnel employed EB1+EIB2: 163.526• Estimated turnover EB (2010): 60.122 MM€• Internal expenditures in R&D: 568.280 M€ (11,2% increase from 2009)• Enterprises related to human health: 67%• Enterprises related to agro-food: 23%• Enterprises related to industrial processing: 10%1EB: biotechology enterprise2EIB:industrial commercial or services’ enterprise, with interests, develpments and products inbiotechnology UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 3 (07/02/2013) Una manera de hacer Europa
  • Contribution of Biotechnology to the Spanish economyContribution toGDP 2010 (%)1,2 GDP Contribution Employment Macroeconomic impact of biotechnologyOECD predictionGDP 2030 (%)2,7 Contribution to GDP (%) Predicted contribution to GDP (%) Employment Predicted employment UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 4 (07/02/2013) Una manera de hacer Europa
  • Classification of Bio-companies Agriculture Food Animal Health Environment Human Health UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 5 (07/02/2013) Una manera de hacer Europa
  • Profile of the Biotechnology enterprise (EB) inSpain • Between 10 and 20 employees • Over 80% of the staff university graduates • Over 25% of the staff devoted to R&D • Less than 5 years of activity • Located mostly in Madrid, Barcelona, Andalucía, País Vasco and Valencia • Linked to prestigious public research institutions UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 6 (07/02/2013) Una manera de hacer Europa
  • Spain: eight BioregionsUNIÓN EUROPEAFondo Europeo deDesarrollo Regional (FEDER) 7 (07/02/2013)Una manera de hacer Europa
  • The Spanish Biotech sector : scientific production (00-08) Source: Genoma EspañaEuropean contribution to world scientific production European contribution to world scientificin biosciences (2000) production in biosciences (2008)United Kingdom Germany Germany United Kingdom France France Italy Italy Netherlands Spain Spain Netherlands Sweden Sweden Belgium Denmark Denmark Belgium Finland Austria Austria Finland Ireland Portugal Portugal Ireland Greece Greece Luxembourg Luxembourg UNIÓN EUROPEA Growth: 47% (annual rate 6%) Fondo Europeo de Desarrollo Regional (FEDER) 8 (07/02/2013) Una manera de hacer Europa
  • The Biotech sector in Spain:evolution of the nº of enterprises (00-08) Source: Genoma España Evolution of EB and EIB UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 9 (07/02/2013) Una manera de hacer Europa
  • The biotech sector in Spain: totalpublic expenditures on R&D&I biotech Source: Genoma EspañaTotal public support for R&D&I in Biotechnology (Mio €) UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 10 (07/02/2013) Una manera de hacer Europa
  • Success stories- 2000: Pfizer invested 12m euros in its European Biometric Centre, which hassupport functions for the rest of Europe and USA.- 2002: Abengoa signed a 35.5million dollar R&D Agreement with the USDepartment of Energy.- 2002: Lilly opened its research centre for medicinal chemistry, one of thebiggest in the world, investing 20 million euros.- 2003: Serono concentrates its global growth-hormone production in Spain.- 2005: GSK opens its research centre for tropical diseases in Spain.- 2009: Genzyme sets up a sales office in Madrid and has a warehouse fordomestic distribution.- 2011: Celgene opens its first research centre outside the USA in Seville. TheCelgene Institute of Translational Research Europe (CITRE) plans to focus onadvanced therapies and regenerative medicine. UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 11 (07/02/2013) Una manera de hacer Europa
  • Spanish Technology Platforms • Biotech Markets • Nanomedicine www.nanomedspain.net/ • Innovative Medicines www.medicamentos- innovadores.org/ • Plants Biotechnology www.invigen.org • Animal Health www.vetmasi.es UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 12 (07/02/2013) Una manera de hacer Europa
  • CDTI DATA 2011 RTD Project Nr .of funded CDTI funding Total and NEOTEC companies investment 92 M€48,116 M€ 64,6 INNPRONTA Nr. of funded CDTI funding Total call companies investment (2 Projects) 17 M€ 27,67 M€ 32,56 Indo-Spanish Nr. of proposals Selected call CDTI-DBT projects First call 2012 7 3 UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 13 (07/02/2013) Una manera de hacer Europa
  • Potential areas for cooperationSPANISH TECHNOLOGICAL STRENGTHS Health and Nano biotechnology Some Developments in 2011 • Oncology,: Advancell, GP Pharm, Ingenasa, Pharmamar, IUCT, Lipopharma, Entrechem, Orizon Genomics • Cardiology/ Neurological: Neuron Pharma, Sanifit, • Oftalmology: Sylentis, Proretina Therapeutics, Biotechnology Institute, Bioftalmic • Vaccines: Archivel Farma, Ferrer, Rovi, Leti • Biotech diagnosis, biomarkers, nanomedicine: Orizon Genomics, Sistemas Genomicos, AB BIOTICs, Genomica, Biobide, Pangaea Biotech, Genetadi Botech, Aromics, Nanotherapy, Nanoinmunotech… • Animal Health: Bionaturis, Ingenasa • Bioinformatic: Integromics, Noray Bio, Biomol Informatics • Regenerative medicine, Cell and Gene therapy: Tigenics (former Cellerix) • Biofuels: Abengoa, Repsol 4th Nano biotechnology Scientific production in the world • Barcelona the 2nd Nano biotech city (1st Boston) UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 14 (07/02/2013) Una manera de hacer Europa
  • Institutions supporting the sector in Spain:Promoting value creation through knowledge www.asebio.com • ASEBIO is the Spanish Asociation of Biocompanies • ASEBIO belongs to and is supported by EUROPABIO, and is a part of CEOE and SEBBM UNIÓN EUROPEA Fondo Europeo de Desarrollo Regional (FEDER) 15 (07/02/2013) Una manera de hacer Europa